Beijing Strong BiotechnologiesInc Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Beijing Strong BiotechnologiesInc wird ein jährliches Gewinn- und Umsatzwachstum von 23.2% bzw. 19.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.6% betragen.

Wichtige Informationen

23.2%

Wachstumsrate der Gewinne

23.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	43.4%
Wachstumsrate der Einnahmen	19.8%
Zukünftige Eigenkapitalrendite	15.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27

Gewinn- und Umsatzwachstumsprognosen

SZSE:300406 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,826	912	N/A	782	2
12/31/2025	2,437	763	N/A	555	2
12/31/2024	2,056	619	N/A	388	2
9/30/2024	1,745	526	524	621	N/A
6/30/2024	1,747	533	521	640	N/A
3/31/2024	1,762	533	436	589	N/A
12/31/2023	1,742	524	437	585	N/A
9/30/2023	1,622	491	375	506	N/A
6/30/2023	1,615	468	297	420	N/A
3/31/2023	1,512	402	299	397	N/A
12/31/2022	1,511	389	300	396	N/A
9/30/2022	1,504	364	313	426	N/A
6/30/2022	1,504	347	304	402	N/A
3/31/2022	1,598	392	280	372	N/A
1/1/2022	1,599	406	276	341	N/A
9/30/2021	1,539	335	244	275	N/A
6/30/2021	1,391	299	193	218	N/A
3/31/2021	1,109	212	112	132	N/A
12/31/2020	848	112	106	123	N/A
9/30/2020	797	202	80	119	N/A
6/30/2020	752	234	67	115	N/A
3/31/2020	781	284	106	154	N/A
12/31/2019	841	332	127	189	N/A
9/30/2019	813	324	134	194	N/A
6/30/2019	787	318	171	247	N/A
3/31/2019	783	303	162	239	N/A
12/31/2018	774	301	183	256	N/A
9/30/2018	755	285	185	252	N/A
6/30/2018	748	279	N/A	210	N/A
3/31/2018	718	280	N/A	209	N/A
12/31/2017	694	273	N/A	208	N/A
9/30/2017	657	266	N/A	205	N/A
6/30/2017	660	259	N/A	251	N/A
3/31/2017	658	259	N/A	254	N/A
12/31/2016	667	272	N/A	243	N/A
9/30/2016	646	266	N/A	228	N/A
6/30/2016	595	259	N/A	145	N/A
3/31/2016	590	255	N/A	144	N/A
12/31/2015	566	245	N/A	143	N/A
9/30/2015	548	222	N/A	130	N/A
6/30/2015	543	218	N/A	165	N/A
3/31/2015	524	218	N/A	146	N/A
12/31/2014	508	211	N/A	157	N/A
9/30/2014	480	205	N/A	170	N/A
12/31/2013	445	181	N/A	147	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300406Das prognostizierte Gewinnwachstum (23.2% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300406Die Erträge des Unternehmens (23.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 300406Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300406Die Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 300406Die Einnahmen des Unternehmens (19.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300406Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.6%).

Beijing Strong BiotechnologiesInc Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

New 90-day high - CN¥24.20

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken